newsfilter
← Latest News
GlobeNewswire·

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,